Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event.
The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor "What This Means" segment featuring CEO Abizer Gaslightwala. The presentation focuses on the company's novel spliceosome modulator payload, PH1, which is being developed as part of their antibody drug conjugates (ADCs) platform for cancer treatment.
During the segment, Gaslightwala discussed ongoing research efforts to understand how the PH1 payload can disrupt key drivers of cancer cell growth, highlighting the company's commitment to advancing their oncology pipeline.
Akari Therapeutics (NASDAQ:AKTX) is advancing research on its novel antibody drug conjugate (ADC) payload PH1, a spliceosome modulator designed for cancer treatment. The company highlighted that PH1 demonstrates multiple mechanisms of action, including cancer cell death induction and immune system activation against tumors.
Key features of PH1 include its ability to target cancers driven by oncogenic factors like KRAS, BRAF, and FGFR3, reduced off-target toxicity through engineered linker technology, and resistance to standard efflux transporters. The company expects to release new preclinical data on PH1's impact against a key oncogenic driver before the end of 2025.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.
The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has released a "Meet the Team" video featuring Mark F. Kubik, their newly appointed Head of Business Development – Oncology. The video, which showcases Kubik, an industry leader known for his oncology expertise and successful transaction record leading to multiple approved therapeutic products, is now available on the company's website under the Investors section.
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. President and CEO Abizer Gaslightwala will present and discuss recent corporate developments on Thursday, May 29, 2025, at 2:20 PM ET. The presentation will be accessible through a webcast, with registration available for interested participants.